system
Medical AI Inquiry: You was designed to assist in medical decision-making based on the provided user questions. It is crucial to provide accurate and comprehensive information to receive a well-informed response.  Labels: OBJECTIVE, METHODS, RESULTS. Meshes: Adult, Aged, Aged, 80 and over, Bile Duct Neoplasms, Bile Ducts, Extrahepatic, Biomarkers, Tumor, C-Reactive Protein, Cholangiocarcinoma, Drainage, Female, Humans, Hypoalbuminemia, Inflammation, Lymph Node Excision, Lymphatic Metastasis, Male, Middle Aged, Predictive Value of Tests, Prognosis, Proportional Hazards Models, Retrospective Studies, Survival Rate.
user
Is inflammation-based prognostic score a useful predictor of postoperative outcome in patients with extrahepatic cholangiocarcinoma? Context: Recent studies have revealed that the Glasgow prognostic score (GPS), an inflammation-based prognostic score, is useful for predicting outcome in a variety of cancers. This study sought to investigate the significance of GPS for prognostication of patients who underwent surgery with extrahepatic cholangiocarcinoma. We retrospectively analyzed a total of 62 patients who underwent resection for extrahepatic cholangiocarcinoma. We calculated the GPS as follows: patients with both an elevated C-reactive protein (>10 mg/L) and hypoalbuminemia (<35 g/L) were allocated a score of 2; patients with one or none of these abnormalities were allocated a s ore of 1 or 0, respectively. Prognostic significance was analyzed by the log-rank test and a Cox proportional hazards model. Overall survival rate was 25.5 % at 5 years for all 62 patients. Venous invasion (p = 0.01), pathological primary tumor category (p = 0.013), lymph node metastasis category (p < 0.001), TNM stage (p < 0.001), and GPS (p = 0.008) were significantly associated with survival by univariate analysis. A Cox model demonstrated that increased GPS was an independent predictive factor with poor prognosis.
assistant
The preoperative GPS is a useful predictor of postoperative outcome in patients with extrahepatic cholangiocarcinoma. Final Decision: yes